Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to 0.78.

  • Iovance Biotherapeutics' Equity Ratio changed N/A to 0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.78, marking a year-over-year change of. This contributed to the annual value of 0.78 for FY2024, which is 415.57% up from last year.
  • Iovance Biotherapeutics' Equity Ratio amounted to 0.78 in Q3 2025.
  • Iovance Biotherapeutics' Equity Ratio's 5-year high stood at 0.81 during Q1 2023, with a 5-year trough of 0.75 in Q4 2023.
  • In the last 3 years, Iovance Biotherapeutics' Equity Ratio had a median value of 0.78 in 2024 and averaged 0.78.
  • Over the last 5 years, Iovance Biotherapeutics' Equity Ratio had its largest YoY gain of 415.57% in 2024, and its largest YoY loss of 331.2% in 2024.
  • Over the past 3 years, Iovance Biotherapeutics' Equity Ratio (Quarter) stood at 0.75 in 2023, then rose by 4.16% to 0.78 in 2024, then dropped by 0.54% to 0.78 in 2025.
  • Its Equity Ratio was 0.78 in Q3 2025, compared to 0.77 in Q2 2025 and 0.79 in Q1 2025.